公开(公告)号：US20250122311A1

公开(公告)日：2025-04-17

申请号：US18681143

申请日：2022-08-05

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Sarel FLEISHMAN ,  Ariel TENNENHOUSE

IPC: C07K16/46 ,  C07K16/30 ,  C07K16/40

Abstract: Provided herein is a method for obtaining a humanized antibody based on a non-human antibody having an affinity to an antigen of interest, that starts from an experimental or model structure, grafts the non-human CDRs on a library of human frameworks and uses restrained/constrained atomistic simulations to relax and rank the designs by energy.

公开(公告)号：US20250092158A1

公开(公告)日：2025-03-20

申请号：US18832710

申请日：2022-08-04

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Deborah FASS ,  Sarel FLEISHMAN ,  Lev KHMELNITSKY ,  Ariel TENNENHOUSE

IPC: C07K16/40 ,  A61K39/00 ,  A61K47/68 ,  G01N33/573

Abstract: The present invention provides humanized monoclonal antibodies that specifically recognize human QSOX1 and inhibit its activity. The humanized antibodies of the present invention were designed following in-silico selection of specific variable region segments, based on their energy scores, and were produced and confirmed to function properly in binding and inhibiting human QSOX1. The present invention further provides pharmaceutical compositions comprising the humanized antibodies and methods for their use in cancer therapy and diagnosis.